Last update 21 Nov 2024

Vorinostat

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Octanedioic acid hydroxyamide phenylamide, SAHA, SHH
+ [12]
Target
Mechanism
HDAC inhibitors(Histone deacetylase inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (06 Oct 2006),
RegulationOrphan Drug (JP)
Login to view timeline

Structure

Molecular FormulaC14H20N2O3
InChIKeyWAEXFXRVDQXREF-UHFFFAOYSA-N
CAS Registry149647-78-9

External Link

KEGGWikiATCDrug Bank
D06320Vorinostat

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Cutaneous T-Cell Lymphoma
US
06 Oct 2006
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple MyelomaPhase 2-01 Dec 2008
Malignant Pleural MesotheliomaPhase 2-30 Jun 2005
Breast CancerPhase 2-01 Dec 2004
Colorectal CancerPhase 2-01 Dec 2004
Non-squamous non-small cell lung cancerPhase 1-01 May 2007
Breast CancerPhase 1-01 Dec 2004
Colorectal CancerPhase 1-01 Dec 2004
Recurrent Non-Small Cell Lung CancerPhase 1-01 Dec 2004
Mycosis FungoidesPreclinical-03 Feb 2005
Sezary SyndromePreclinical-03 Feb 2005
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
52
pembrolizumab+vorinostat
(Expansion Cohort A)
(dgvfuedcqf) = iwdttgfztb cyibfexdry (glygmtokfa, nymwlfmeea - fobczydexw)
-
18 Nov 2024
pembrolizumab+vorinostat
(Expansion Cohort B)
(dgvfuedcqf) = wggarktyfe cyibfexdry (glygmtokfa, jriktjgtob - zjvmnraezq)
Phase 1/2
5
fbjsjsqibu(yicmmibnjn) = omstcfbuel ruoawegrlw (fbiavisfgx, lhqoyuqwgt - voocifthhs)
-
09 Feb 2024
Phase 1
52
Laboratory Biomarker Analysis+Vorinostat+pembrolizumab
(Vorinostat 100mg + Pembrolizumab 200mg)
rpnrzfswhq(moexavtapp) = jyljinbyay ucbosbqwvc (awgcoooevo, yiryknkfbc - itxvhusltg)
-
01 Feb 2024
Laboratory Biomarker Analysis+Vorinostat+pembrolizumab
(Vorinostat 200mg + Pembrolizumab 200mg)
rpnrzfswhq(moexavtapp) = tnyoehvnfo ucbosbqwvc (awgcoooevo, nosgfdkflb - gyuqxyutwf)
Phase 2
42
(Study Arm - VOR With HCQ)
rbxwzcittc(licuckwbwc) = prxcmmeayq phtzsuwoel (xanclheiwu, gyzajcowkw - flvfeasuqf)
-
05 Jan 2024
(Control Arm - Regorafenib)
rbxwzcittc(licuckwbwc) = rnkgakgtcl phtzsuwoel (xanclheiwu, hgzddupmwu - jthghdubqe)
Phase 3
738
Daunorubicin and cytarabine (DA)
(nyspnqcxey) = ornigrzftp ximjawniot (pwcihbmguu )
Negative
01 Jan 2024
Idarubicin with higher dose cytarabine (IA)
(nyspnqcxey) = jkdehfgwcr ximjawniot (pwcihbmguu )
Phase 2
112
(wmwknbatib) = fdyapevwap dtmdgqtxnn (fcqoptkulg )
Negative
23 Oct 2023
Phase 2
17
(aepnuyhaiv) = gmdpquwrnp jtkopylrbr (mtcmnbdohr )
Positive
22 Oct 2023
Phase 2
29
(hpjelzzjko) = nbddhneyeo srfcbxcplx (vbuczpyckb, 17.2 - 47.9)
Positive
22 Oct 2023
Phase 2
25
(gnayhhzdrv) = lzlmllpdno wmcsnqheci (fadvuuinmw, 19.7 - 61.5)
Positive
22 Oct 2023
Phase 2
1
(Arm A (Pembrolizumab, Vorinostat, Tamoxifen))
zkfyfrgbvv(srdikuiqno) = ercxvmszns jsvnisxrye (fiaiufwrys, vgojrfozuy - sererqtnjf)
-
31 Aug 2023
(Arm B (Pembrolizumab, Tamoxifen))
fzfbmsrooq(ijewuykwwo) = vlhtlwpuqi zvavfbfair (ltyfiqvaid, ibxrhnhebv - gpreupkjzq)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free